Ypsomed and ten23 health collaborate for the commercialization of the YpsoDose patch injector

Press Releases Ypsomed Group

Burgdorf – Ypsomed enters a partnership with ten23 health, a global Swiss contract development and manufacturing organization. The aim of this collaboration is to advance the commercialization of the YpsoDose wearable injector for the subcutaneous self-injection of large-volume doses. ten23’s drug development, filling and device assembly expertise will significantly contribute to the product offering.

Témata:
Platforms & Operational Excellence

Čtěte více …

mylife Loop improves health of pregnant women with type 1 diabetes and their babies

Press Releases Ypsomed Group

Burgdorf – Pregnant women with type 1 diabetes and their babies benefit from treatment with a hybrid closed loop system based on the CamAPS FX algorithm. This is demonstrated by the AiDAPT clinical study, which clinical outcomes were published in the New England Journal of Medicine and the experience of the pregnant women in Diabetes Technology and Therapeutics, both on 5 October 2023. The algorithm of Ypsomed's mylife Loop, the CamAPS FX app is the only automated insulin delivery (AID) algorithm approved for pregnant women with type 1 diabetes.

Témata:
Innovation & Digital Health

Čtěte více …

Ypsomed enhances self-injection device platforms with integrated human factors services

Press Releases Ypsomed Group

Burgdorf – Ypsomed announces new Human Factors (HF) services for its pharmaceutical partners to reinforce its position as a leading developer and manufacturer of self-injection solutions. By enhancing its device platform offering with integrated end-to-end HF services, Ypsomed is championing a comprehensive service approach to combination product development that de-risks regulatory approval and expedites time-to-market for its partners. To do so, Ypsomed has entered into a strategic partnership with Interface Analysis Associates LLC (IAA), a leading HF service provider with long-standing expertise in supporting the pharmaceutical industry along the full combination product development journey. 

Témata:
Platforms & Operational Excellence

Čtěte více …

Annual General Meeting of Ypsomed approves all proposals

Press Releases Ypsomed Group

Burgdorf – The Annual General Meeting of Ypsomed Holding AG (SIX: YPSN) approved all proposals of the Board of Directors on 28 June 2023. More than 360 shareholders attended the event in Burgdorf. They confirmed all members of the Board of Directors in their office and re-elected Gilbert Achermann as Chairman of the Board of Directors.

Témata:
Management

Čtěte více …

People with acute and chronic conditions are supported in their self-treatment by the digital therapy management of Ypsomed and S3 Conncted Health.

Ypsomed partners with S3 Connected Health to expand its digital health offering

Press Releases Ypsomed Group

Burgdorf – Ypsomed (SIX: YPSN) will expand its offering of digital health solutions together with S3 Connected Health in the future. S3 Connected Health, headquartered in Dublin, Ireland is a specialist digital health partner for life science companies. The new offering will allow Ypsomed’s biopharma customers to quickly launch therapy-specific digital patient solutions. People with acute and chronic diseases can thus be supported fully in their therapy management and the outcome of their treatment can be enhanced.

Témata:
Innovation & Digital Health

Čtěte více …